195 related articles for article (PubMed ID: 7683043)
1. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.
Kelly WK; Scher HI; Mazumdar M; Vlamis V; Schwartz M; Fossa SD
J Clin Oncol; 1993 Apr; 11(4):607-15. PubMed ID: 7683043
[TBL] [Abstract][Full Text] [Related]
2. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
Small EJ; McMillan A; Meyer M; Chen L; Slichenmyer WJ; Lenehan PF; Eisenberger M
J Clin Oncol; 2001 Mar; 19(5):1304-11. PubMed ID: 11230472
[TBL] [Abstract][Full Text] [Related]
3. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer.
Smith DC; Dunn RL; Strawderman MS; Pienta KJ
J Clin Oncol; 1998 May; 16(5):1835-43. PubMed ID: 9586898
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
Kwak C; Jeong SJ; Park MS; Lee E; Lee SE
J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.
D'Amico AV; Chen MH; Cox MC; Dahut W; Figg WD
Urology; 2005 Sep; 66(3):571-6. PubMed ID: 16140080
[TBL] [Abstract][Full Text] [Related]
6. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
8. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
9. Acid phosphatase: defining a role in androgen-independent prostate cancer.
Steineck G; Kelly WK; Mazumdar M; Vlamis V; Schwartz M; Scher HI
Urology; 1996 May; 47(5):719-26. PubMed ID: 8650872
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.
Furuya Y; Nagakawa O; Fuse H
Urol Int; 2003; 70(3):195-9. PubMed ID: 12660456
[TBL] [Abstract][Full Text] [Related]
11. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer.
Scher HI; Kelly WM; Zhang ZF; Ouyang P; Sun M; Schwartz M; Ding C; Wang W; Horak ID; Kremer AB
J Natl Cancer Inst; 1999 Feb; 91(3):244-51. PubMed ID: 10037102
[TBL] [Abstract][Full Text] [Related]
12. PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.
Robinson D; Sandblom G; Johansson R; Garmo H; Aus G; Hedlund PO; Varenhorst E;
Urology; 2008 Oct; 72(4):903-7. PubMed ID: 18639324
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
14. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
[TBL] [Abstract][Full Text] [Related]
15. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.
Chauvet B; Félix-Faure C; Lupsascka N; Fijuth J; Brewer Y; Davin JL; Kirscher S; Reboul F
J Clin Oncol; 1994 Jul; 12(7):1402-7. PubMed ID: 7517443
[TBL] [Abstract][Full Text] [Related]
17. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher HI; Kelly WK
J Clin Oncol; 1993 Aug; 11(8):1566-72. PubMed ID: 7687666
[TBL] [Abstract][Full Text] [Related]
18. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer.
Fowler JE; Pandey P; Seaver LE; Feliz TP; Braswell NT
J Urol; 1995 Jun; 153(6):1860-5. PubMed ID: 7538599
[TBL] [Abstract][Full Text] [Related]
19. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer.
Furuya Y; Akimoto S; Akakura K; Igarashi T; Murakami S; Shimazaki J; Ito H
Urol Int; 1998; 60(1):28-32. PubMed ID: 9519418
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma.
Ghossein RA; Rosai J; Scher HI; Seiden M; Zhang ZF; Sun M; Chang G; Berlane K; Krithivas K; Kantoff PW
Urology; 1997 Jul; 50(1):100-5. PubMed ID: 9218026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
